While these pathways are known to play critical roles in brain tumors, the levels, or ability, of ST6GAL1, ST6GAL2, or α2,6 sialylation to modulate BTIC signaling or maintenance to increase glioma growth has not been investigated. This evidence concerns the gene ST6GAL1 and brain neoplasm.